These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29446084)

  • 1. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.
    Kern Sliwa J; Savitz A; Nuamah I; Mathews M; Gopal S; Elefant E; Najarian D; Alphs L
    Perspect Psychiatr Care; 2018 Oct; 54(4):530-538. PubMed ID: 29446084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
    Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
    Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
    Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
    Brown B; Turkoz I; Mancevski B; Mathews M
    Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Hough D; Mathews M
    Int Clin Psychopharmacol; 2017 Nov; 32(6):329-336. PubMed ID: 28806194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
    Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
    Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
    Li X; Ye C; Zhang W; Jia M; Wang G
    CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.
    Fu DJ; Turkoz I; Walling D; Lindenmayer JP; Schooler NR; Alphs L
    Schizophr Res; 2018 Feb; 192():185-193. PubMed ID: 28454922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
    Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
    J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 16. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
    T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
    Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
    Gopal S; Gogate J; Pungor K; Kim E; Singh A; Mathews M
    Neuropsychiatr Dis Treat; 2020; 16():681-690. PubMed ID: 32184607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.